Join to View Full Profile
300 George StSte 901New Haven, CT 06511
Phone+1 203-785-2095
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Benjamin Kelmendi, MD is a board certified psychiatrist in New Haven, Connecticut. He is currently licensed to practice medicine in Connecticut.
Education & Training
Yale-New Haven Medical CenterResidency, Psychiatry, 2011 - 2015
University of Vermont College of Medicine
Certifications & Licensure
CT State Medical License 2013 - 2026- CT State Medical License 2013 - 2026
American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 2 citationsPsilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.Anthony L Back, Timara K Freeman-Young, Ladybird Morgan, Tanmeet Sethi, Kelsey K Baker
JAMA Network Open. 2024-12-02 - 1 citationsPsychedelic medicine in psychiatry residency training: a survey of psychiatric residency program directors.Mary E Yaden, Terence H W Ching, Noam Goldway, Daniel E Roberts, Jamila Hokanson
International Review of Psychiatry. 2024-12-01 - 2 citationsNovel Pharmacologic and Other Somatic Treatment Approaches for Posttraumatic Stress Disorder in Adults: State of the Evidence.Lauren M Sippel, Jessica L Hamblen, Benjamin Kelmendi, Jonathan E Alpert, Linda L Carpenter
The American Journal of Psychiatry. 2024-12-01
Authored Content
- Developing Image Sets for Inducing Obsessive-Compulsive Checking SymptomsApril 2018
- Developing Image Sets for Inducing Obsessive-Compulsive Checking SymptomsApril 2018
Press Mentions
Changing Lives with Psychedelics: How Connecticut Researchers Are Using Magic Mushrooms to Help People Overcome Depression, OCDNovember 17th, 2022- NIH: It’s Time to Make Your Mark on the Renaissance of Medicinal PsychedelicsJune 2nd, 2021
- Global Psychedelic Therapeutics Market Is Projected to Grow at an Annualized Rate of ~15%, Till 2030January 12th, 2021
Grant Support
- The neural correlates of the effects of psilocybin in OCD: randomized controlled studyYALE UNIVERSITY2021–2025
